Items tagged with Treatment
Shorter regimen for resistant TB could save $740 million a year (post)
17 December 2022: An analysis yesterday by researchers with the TB Alliance, Stop TB Partnership, World Health Organization (WHO), and other groups estimates that the recently approved BPaLM/BPaL treatment regimen for drug-resistant tuberculosis (DR-TB) could save governments up to $740 million a year, enough to supply more than 400,000 people with almost a year's worth of DR-TB treatment.
Mini bio-devices could help TB patients stick to their treatments (post)
Imagine the scenario: you’ve been told you have a disease that will kill you. But, the doctor adds, your life can be saved if you diligently take your medication. Don’t skip a day, don’t skip a dosage. Soon, however, you discover that the medication has a slew of side effects, including a loss of appetite, fatigue, and nausea. So you do stop.
Experts call for better screening and treatment of TB during pregnancy (post)
Busisiwe Beko, from Khayelitsha in the Western Cape, was diagnosed with drug-resistant tuberculosis (DR-TB) while she was pregnant. She remembers it as a very difficult period in her life.
Rifamycin Drug-Drug Interactions: A Guide for Primary Care Providers Treating Latent Tuberculosis Infection (post)
Rifamycin Drug-Drug Interactions: A Guide for Primary Care Providers Treating Latent Tuberculosis Infection was created through a collaboration of the State of California Department of Public Health, Tuberculosis Control Branch (CDPH), the Rutgers Ernest Mario School of Pharmacy (EMSOP), the Rutgers Global Tuberculosis Institute (GTBI), and the Curry International Tuberculosis Center (CITC).
With daily injections and two years of costly treatment, TB survivors look for a ray of light (post)
The 1/4/6x24 (one, four, six by 2024) campaign calls for TB patients to have access to evidence-based, long-awaited, shorter, less toxic treatment. But without mass availability of drugs, can India afford to adopt the protocol, ask experts.
High risk of pulmonary hypertension found with history of TB treatment (post)
Pulmonary hypertension (PH) is estimated to be highly prevalent among people with a history of tuberculosis (TB) who successfully completed treatment, a study in South Africa reports.
Study shows FDA-approved TB regimen may not work against the deadliest form of TB due to multidrug-resistant strains (post)
Findings from a Johns Hopkins Children's Center study in animal models show that a U.S. Food and Drug Administration (FDA)-approved antibiotic regimen for multidrug-resistant (MDR) tuberculosis (TB) may not work for TB meningitis. Studies in a small number of people also provide evidence that a new combination of drugs is needed to develop effective treatments for TB meningitis due to MDR strains.
Final hearing in TB drug patent case ends, verdict likely in a month (post)
New Delhi: The Indian Patent Office had held its final hearing on a challenge filed by two tuberculosis survivors to prevent the Indian arm of drugmaker Johnson & Johnson from extending its patent on bedaquiline, used against drug-resistant TB, beyond the primary patent’s expiry in July.
Launch of global individual patient data platform for TB treatment (post)
31 January 2023: WHO is announcing the publicly accessible global individual patient data (IPD) platform for tuberculosis treatment (TB-IPD), an initiative that will increase the knowledge base for normative guidance on optimal treatment modalities for tuberculosis (TB) and stimulate TB research.
Qurient Co. Ltd. and TB Alliance announce exclusive license agreement for telacebec (Q203), a new anti-TB agent (post)
SEONGNAM-SI, South Korea and NEW YORK, US, February 3, 2023: Qurient Co. Ltd. (“Qurient”, KRX: 115180), a clinical-stage biotechnology company based in South Korea, and TB Alliance, a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs, announced today that they have entered into a license agreement to develop and commercialize telacebec (Q203), a first-in-class orally available cytochrome bc1 inhibitor for the treatment of tuberculosis (TB) and other non-tuberculosis mycobacterium infections.
Page 67 of 108 · Total posts: 0
←First 66 67 68 Last→